Amgen share price today

Name: Amgen Share Price Today (NASDAQ: AMGN) - Amgen Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

(AMGN)

Amgen share price is $274.81 & ₹23,743.58 as on 22 Jan 2025, 2.30 'hrs' IST

$274.81

▲

2.7

(0.99%)

Market is closed - opens 8 PM, 22 Jan 2025

View live Amgen share price in Dollar and Rupees. Guide to invest in Amgen stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Amgen, along with analyst recommendations, forecasts, and comprehensive financials.

Amgen share price movements

Today's Low: $270.88
Today's High: $276.45
$274.81
1.43%
Downside
Day's Volatility :2.02%
Upside
0.59%
52 Weeks Low: $253.30
52 Weeks High: $346.85
$274.81
7.83%
Downside
52 Weeks Volatility :26.97%
Upside
20.77%

Amgen Returns

Period	Amgen Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-12.73%	-7.2%	5.7%
6 Months	-18.12%	-5.7%	9.0%
1 Year	-11.33%	0.1%	27.8%
3 Years	21.55%	8.3%	42.6%

Amgen Key Statistics

in dollars & INR

Previous Close	$272.11
Open	$272.14
Today's High	$276.45
Today's Low	$270.875
Market Capitalization	$146.3B
Today's Volume	$3.1M
52 Week High	$346.85
52 Week Low	$253.3
Revenue TTM	$32.5B
EBITDA	$12.2B
Earnings Per Share (EPS)	$7.84
PE Ratio	34.71
Dividend Yield	3.5%
Profit Margin	13.0%
Quarterly Earnings Growth YOY	0.62%
Return On Equity TTM	55.72%

How to invest in Amgen from India?

It is very easy for Indian residents to invest directly in Amgen from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Amgen stock in both Indian Rupees (INR) and US Dollars (USD). Search for Amgen or AMGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Amgen or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Amgen shares which would translate to 0.003 fractional shares of Amgen as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Amgen, in just a few clicks!

Returns in Amgen for Indian investors in Rupees

Investment Value

₹1,00,000

Amgen investment value today

Current value as on today

₹92,628

Returns

₹7,372

(-7.37%)

Returns from Amgen Stock

₹11,326 (-11.33%)

Dollar Returns

₹3,954 (+3.95%)

Indian investors sentiment towards Amgen

-72.99%

Period: Oct 23, 2024 to Jan 21, 2025. Change in 30 Days versus previous period

Investment in Amgen from India has reduced in the last 30 days as on Jan 22, 2025. -72.99% less purchase transactions for Amgen in the last 30 days versus the previous period.

-58%

Period: Oct 23, 2024 to Jan 21, 2025. Change in 30 Days versus previous period

Search volume for Amgen on INDmoney from India has reduced in the last 30 days as on Jan 22, 2025. -58% less investors are searching Amgen in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Amgen

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	6999	0.00	0.89%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	810	0.00	1.14%
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	17000	0.00	1.18%
Motilal Oswal S&P 500 Index Fund Direct Growth	4637	-277.43	0.28%

Global Institutional Holdings in Amgen

Vanguard Group Inc
9.74%
BlackRock Inc
8.60%
State Street Corp
5.45%
Morgan Stanley - Brokerage Accounts
2.73%
PRIMECAP Management Company
2.65%
Geode Capital Management, LLC
2.26%

Analyst Recommendation on Amgen

Buy

56%Buy

35%Hold

8%Sell

Based on 37 Wall street analysts offering stock ratings for Amgen(by analysts ranked 0 to 5 stars)

Based on 37 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Amgen

What analysts predicted

Upside of 15.44%

Target:

$317.24

Current:

$274.81

Insights on Amgen

Price Movement
In the last 3 months, AMGN stock has moved down by -14.9%
Increasing Revenue
Amgen Inc. has shown positive revenue growth over the last three quarters. The revenue increased from $7.39 billion to $8.50 billion, with an average growth rate of 6.6% per quarter.
Increasing Net Profit
Amgen Inc. has shown a strong performance in its net profit over the past three quarters. The net profit has increased significantly from a loss of $113.0 million to $2.83 billion. This represents an average growth rate of 94.4% in net profit each quarter.
AMGN vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 15.0% return, outperforming this stock by 27.3%
AMGN vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 198.6% return, outperforming this stock by 179.1%
Price to Sales
Amgen Inc. has a Price-to-Sales Ratio of 4.5, meaning that investors are willing to pay $4.5 for every $1 of sales the company generates. In comparison, Eli Lilly And Company has a much higher Price-to-Sales Ratio of 16.4, indicating that investors value its sales more highly than Amgen's.

Amgen Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$23.7B	↑ 3.93%
Net Income	$8.4B	↑ 324.15%
Net Profit Margin	35.35%	↑ 26.69%

	FY19	Y/Y Change
Revenue	$23.4B	↓ 1.62%
Net Income	$7.8B	↓ 6.58%
Net Profit Margin	33.57%	↓ 1.78%

	FY20	Y/Y Change
Revenue	$25.4B	↑ 8.83%
Net Income	$7.3B	↓ 7.37%
Net Profit Margin	28.57%	↓ 5.0%

	FY21	Y/Y Change
Revenue	$26.0B	↑ 2.18%
Net Income	$5.9B	↓ 18.87%
Net Profit Margin	22.68%	↓ 5.89%

	FY22	Y/Y Change
Revenue	$26.3B	↑ 1.32%
Net Income	$6.6B	↑ 11.18%
Net Profit Margin	24.89%	↑ 2.21%

	FY23	Y/Y Change
Revenue	$28.2B	↑ 7.09%
Net Income	$6.7B	↑ 2.52%
Net Profit Margin	23.83%	↓ 1.06%

	Q2 FY23	Q/Q Change
Revenue	$7.0B	↑ 14.43%
Net Income	$1.4B	↓ 51.46%
Net Profit Margin	19.74%	↓ 26.8%

	Q3 FY23	Q/Q Change
Revenue	$6.9B	↓ 1.19%
Net Income	$1.7B	↑ 25.45%
Net Profit Margin	25.06%	↑ 5.32%

	Q4 FY23	Q/Q Change
Revenue	$8.2B	↑ 18.73%
Net Income	$767.0M	↓ 55.66%
Net Profit Margin	9.36%	↓ 15.7%

	Q1 FY24	Q/Q Change
Revenue	$7.4B	↓ 9.76%
Net Income	$-113.0M	↓ 114.73%
Net Profit Margin	-1.53%	↓ 10.89%

	Q2 FY24	Q/Q Change
Revenue	$8.3B	↑ 12.67%
Net Income	$746.0M	↓ 760.18%
Net Profit Margin	8.95%	↑ 10.48%

	Q3 FY24	Q/Q Change
Revenue	$8.5B	↑ 2.04%
Net Income	$2.8B	↑ 279.36%
Net Profit Margin	33.28%	↑ 24.33%

	FY18	Y/Y Change
Profit	$19.6B	↑ 4.61%

	FY19	Y/Y Change
Profit	$19.0B	↓ 3.26%

	FY20	Y/Y Change
Profit	$19.3B	↑ 1.36%

	FY21	Y/Y Change
Profit	$19.5B	↑ 1.35%

	FY22	Y/Y Change
Profit	$19.9B	↑ 2.01%

	FY23	Y/Y Change
Profit	$19.7B	↓ 0.89%

	Q2 FY23	Q/Q Change
Profit	$5.2B	↑ 17.97%

	Q3 FY23	Q/Q Change
Profit	$5.1B	↓ 1.47%

	Q4 FY23	Q/Q Change
Profit	$5.1B	↓ 0.26%

	Q1 FY24	Q/Q Change
Profit	$4.2B	↓ 17.47%

	Q2 FY24	Q/Q Change
Profit	$5.1B	↑ 21.47%

	Q3 FY24	Q/Q Change
Profit	$5.2B	↑ 1.88%

	FY18	Y/Y Change
Operating Cash Flow	$11.3B	↑ 1.06%
Investing Cash Flow	$14.3B	↓ 456.34%
Financing Cash Flow	$-22.5B	↑ 241.07%

	FY19	Y/Y Change
Operating Cash Flow	$9.2B	↓ 19.0%
Investing Cash Flow	$5.7B	↓ 60.19%
Financing Cash Flow	$-15.8B	↓ 29.89%

	FY20	Y/Y Change
Operating Cash Flow	$10.5B	↑ 14.72%
Investing Cash Flow	$-5.4B	↓ 194.61%
Financing Cash Flow	$-4.9B	↓ 69.13%

	FY21	Y/Y Change
Operating Cash Flow	$9.3B	↓ 11.77%
Investing Cash Flow	$733.0M	↓ 113.57%
Financing Cash Flow	$-8.3B	↑ 69.94%

	FY22	Y/Y Change
Operating Cash Flow	$9.7B	↑ 4.97%
Investing Cash Flow	$-6.0B	↓ 924.56%
Financing Cash Flow	$-4.0B	↓ 51.19%

	FY23	Y/Y Change
Operating Cash Flow	$8.5B	↓ 12.86%
Investing Cash Flow	$-26.2B	↑ 333.55%
Financing Cash Flow	$21.0B	↓ 621.38%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$4.1B	↑ 286.18%
Investing Cash Flow	$-211.0M	↓ 115.54%
Financing Cash Flow	$-1.2B	↓ 105.63%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$2.8B	↓ 32.83%
Investing Cash Flow	$-262.0M	↑ 24.17%
Financing Cash Flow	$-2.0B	↑ 65.7%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$538.0M	↓ 80.51%
Investing Cash Flow	$-27.1B	↑ 10239.31%
Financing Cash Flow	$2.8B	↓ 237.36%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$689.0M	↑ 28.07%
Investing Cash Flow	$-217.0M	↓ 99.2%
Financing Cash Flow	$-1.7B	↓ 162.02%

Amgen Technicals Summary

Sell

Neutral

Buy

Amgen is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Amgen Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amgen Inc.	3.07%	-18.12%	-11.33%	21.55%	21.82%
Eli Lilly And Company	-8.86%	-13.67%	17.89%	208.77%	433.8%
Johnson & Johnson	1.21%	-5.2%	-7.3%	-9.09%	-0.11%
Merck & Co. Inc.	-1.46%	-23.57%	-19.69%	22.09%	11.93%
Novo Nordisk A/s	-11.3%	-38.43%	-23.1%	69.8%	165.32%
Abbvie Inc	-3.83%	-2.04%	3.05%	30.61%	106.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amgen Inc.	34.71	34.71	1.94	19.62	0.56	0.05	0.04	14.0
Eli Lilly And Company	78.12	78.12	0.69	12.98	0.65	0.14	0.01	15.83
Johnson & Johnson	24.34	24.34	0.86	9.97	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.49	20.49	0.07	7.69	0.28	0.11	0.03	17.58
Novo Nordisk A/s	26.86	26.86	1.28	23.09	0.89	0.21	0.02	27.07
Abbvie Inc	59.78	59.78	0.41	10.75	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amgen Inc.	Buy	$146.3B	21.82%	34.71	13.0%
Eli Lilly And Company	Buy	$652.7B	433.8%	78.12	20.48%
Johnson & Johnson	Buy	$354.0B	-0.11%	24.34	16.74%
Merck & Co. Inc.	Buy	$247.7B	11.93%	20.49	19.23%
Novo Nordisk A/s	Buy	$352.9B	165.32%	26.86	35.01%
Abbvie Inc	Buy	$303.2B	106.62%	59.78	9.22%

Amgen Dividend announcements

Amgen Dividends March, 2025
In the quarter ending March,2025. Amgen has declared dividend of $2.38
Read More

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Organization	Amgen
Employees	26700
CEO	Mr. Robert A. Bradway
Industry	Health Technology

Management People of Amgen

Name	Title
Mr. Robert A. Bradway	Chairman, CEO & President
Mr. Peter H. Griffith	Executive VP & CFO
Mr. Esteban Santos	Executive Vice President of Operations
Dr. David M. Reese M.D.	Executive VP & CTO
Mr. Murdo Gordon	Executive Vice President of Global Commercial Operations
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Finance
Mr. Scott Skellenger	Senior VP & Chief Information Officer
Dr. Howard Y. Chang M.D., Ph.D.	Senior VP of Global Research & Chief Scientific Officer
Justin G. Claeys	Vice President of Investor Relations
Mr. Jonathan P. Graham J.D.	Executive VP, General Counsel & Secretary

Important FAQs about investing in Amgen from India :

What is Amgen share price today?

Amgen share price today stands at $274.81, Open: $272.14 ; Previous Close: $272.11 ; High: $276.45 ; Low: $270.88 ; 52 Week High: $346.85 ; 52 Week Low: $253.30. The stock opens at $272.14, after a previous close of $272.11. The stock reached a daily high of $276.45 and a low of $270.88, with a 52-week high of $346.85 and a 52-week low of $253.30.

Can Indians buy Amgen shares?

Yes, Indians can invest in the Amgen (AMGN) from India.

With INDmoney, you can buy Amgen at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Amgen at zero transaction cost.

How can I buy Amgen shares from India?

It is very easy to buy Amgen from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Amgen be purchased?

Yes, you can buy fractional shares of Amgen with INDmoney app.

What are the documents required to start investing in Amgen stocks?

To start investing in Amgen, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.